Merus Announces Publication of Abstracts on MCLA-129 for
- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m....
Source: globenewswire.com
Stay updated with breaking news from Merus Nv. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m....
(2023-10-23 | NDAQ:MRUS) Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
An exhaustive analysis of Merus NV's intrinsic value, financial strength, and future prospects